Sunshine Biopharma Statistics Share Statistics Sunshine Biopharma has 4.56M
shares outstanding. The number of shares has increased by 272.11%
in one year.
Shares Outstanding 4.56M Shares Change (YoY) 272.11% Shares Change (QoQ) 68.22% Owned by Institutions (%) 0% Shares Floating 4.55M Failed to Deliver (FTD) Shares 2,336 FTD / Avg. Volume 1.93%
Short Selling Information The latest short interest is 305.9K, so 6.71% of the outstanding
shares have been sold short.
Short Interest 305.9K Short % of Shares Out 6.71% Short % of Float 6.72% Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -0.41 and the forward
PE ratio is 17.31.
Sunshine Biopharma's PEG ratio is
0.
PE Ratio -0.41 Forward PE 17.31 PS Ratio 0.06 Forward PS 0.1 PB Ratio 0.09 P/FCF Ratio -0.14 PEG Ratio 0
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Sunshine Biopharma.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 4.11,
with a Debt / Equity ratio of 0.04.
Current Ratio 4.11 Quick Ratio 2.33 Debt / Equity 0.04 Debt / EBITDA -0.18 Debt / FCF -0.06 Interest Coverage -662.41
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $670.65K Profits Per Employee $-98.73K Employee Count 52 Asset Turnover 1.14 Inventory Turnover 2.15
Taxes Income Tax -235K Effective Tax Rate 4.38%
Stock Price Statistics The stock price has increased by -51.39% in the
last 52 weeks. The beta is 0.24, so Sunshine Biopharma's
price volatility has been higher than the market average.
Beta 0.24 52-Week Price Change -51.39% 50-Day Moving Average 1.51 200-Day Moving Average 2.12 Relative Strength Index (RSI) 40.27 Average Volume (20 Days) 120,735
Income Statement In the last 12 months, Sunshine Biopharma had revenue of 34.87M
and earned -5.13M
in profits. Earnings per share was -7.32.
Revenue 34.87M Gross Profit 10.67M Operating Income -5.81M Net Income -5.13M EBITDA -5.15M EBIT -5.36M Earnings Per Share (EPS) -7.32
Full Income Statement Balance Sheet The company has 9.69M in cash and 952.48K in
debt, giving a net cash position of 8.73M.
Cash & Cash Equivalents 9.69M Total Debt 952.48K Net Cash 8.73M Retained Earnings -69.04M Total Assets 30.56M Working Capital 19.65M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -12.53M
and capital expenditures -2.32M, giving a free cash flow of -14.85M.
Operating Cash Flow -12.53M Capital Expenditures -2.32M Free Cash Flow -14.85M FCF Per Share -21.16
Full Cash Flow Statement Margins Gross margin is 30.6%, with operating and profit margins of -16.67% and -14.72%.
Gross Margin 30.6% Operating Margin -16.67% Pretax Margin -15.4% Profit Margin -14.72% EBITDA Margin -14.78% EBIT Margin -16.67% FCF Margin -42.59%
Dividends & Yields SBFM does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for SBFM is $15,
which is 971.4% higher than the current price. The consensus rating is "Buy".
Price Target $15 Price Target Difference 971.4% Analyst Consensus Buy Analyst Count 1
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Aug 8, 2024. It was a
backward
split with a ratio of 1:20.
Last Split Date Aug 8, 2024 Split Type backward Split Ratio 1:20
Scores Altman Z-Score -1.24 Piotroski F-Score 1
